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A recent genome-wide association study reported five loci for which there was strong, but sub-genome-wide significant
evidence for association with multiple sclerosis risk. The aim of this study was to evaluate the role of these potential risk
loci in a large and independent data set of 20 000 subjects. We tested five single nucleotide polymorphisms rs228614
(MANBA), rs630923 (CXCR5), rs2744148 (SOX8), rs180515 (RPS6KB1), and rs6062314 (ZBTB46) for association with multiple
sclerosis risk in a total of 8499 cases with multiple sclerosis, 8765 unrelated control subjects and 958 trios of European descent.
In addition, we assessed the overall evidence for association by combining these newly generated data with the results from
the original genome-wide association study by meta-analysis. All five tested single nucleotide polymorphisms showed consist-
ent and statistically significant evidence for association with multiple sclerosis in our validation data sets (rs228614: odds
ratio = 0.91, P = 2.4  106; rs630923: odds ratio = 0.89, P = 1.2  104; rs2744148: odds ratio = 1.14, P = 1.8  106;
rs180515: odds ratio = 1.12, P = 5.2  107; rs6062314: odds ratio = 0.90, P = 4.3  103). Combining our data with results
from the previous genome-wide association study by meta-analysis, the evidence for association was strengthened further,
surpassing the threshold for genome-wide significance (P5 5  108) in each case. Our study provides compelling evidence
that these five loci are genuine multiple sclerosis susceptibility loci. These results may eventually lead to a better understanding
of the underlying disease pathophysiology.
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Introduction
Multiple sclerosis is the most common inflammatory demyelinating
disease of the CNS that is likely caused by an interplay of genetic
and environmental risk factors. Apart from several independent
association signals in the HLA (human leukocyte antigen) region
on chromosome 6p21, a recent genome-wide association study
(GWAS) in multiple sclerosis has reported 52 loci exerting
small to moderate risk effects (IMSGC and WTCCC2, 2011).
In addition, five additional loci provided strong support for asso-
ciation (P5 5  107) in that GWAS, but failed to meet current
criteria for genome-wide significance (P5 5  108). The most
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significantly associated single-nucleotide polymorphisms (SNPs) in
these regions were rs228614 in MANBA (mannosidase, beta A,
lysosomal), rs630923 upstream of CXCR5 (chemokine C-X-C
motif receptor 5), rs2744148 downstream of SOX8 (sex determin-
ing region Y-box 8), rs180515 downstream of RPS6KB1 (riboso-
mal protein S6 kinase, 70 kDa, polypeptide 1), and rs6062314 in
ZBTB46 (zinc finger and BTB domain containing 46) (IMSGC and
WTCCC2, 2011). Given the lack of genome-wide significance,
independent validation efforts are needed to further discern the
putative role of these loci in multiple sclerosis risk. To this end, we
have tested these five SNPs for association with multiple sclerosis
risk in a multicentric study comprising 20 138 subjects of European
descent who were independent of the original GWAS sample
(IMSGC and WTCCC2, 2011).
Materials and methods
Power analysis
Power was estimated using the Genetic Power Calculator (Purcell et al.,
2003) assuming a one-sided a of 0.01 and a disease prevalence of 0.1%.
Data sets
The current study included a total of 8805 multiple sclerosis cases and
8981 unrelated control subjects of self-reported European descent from
Germany, Spain, France, The Netherlands, and Australia, as well as 963
trios from the UK. Subjects were selected specifically to be non-over-
lapping with the original study (IMSGC and WTCCC2, 2011). Diagnosis
of multiple sclerosis was established according to standard diagnostic
criteria (Poser et al., 1983; McDonald et al., 2001). All samples were
collected with informed written consent and appropriate ethical approval
at the respective sites. The effective sample size after quality control
comprised 8499 multiple sclerosis cases, 8765 unrelated control subjects,
and 958 trios (see below and Supplementary Table 1).
Genotyping and quality control
Genotyping for the German, Spanish and British samples was per-
formed at the individual sites using single-assay allelic discrimination
assays based on TaqMan chemistry following the manufacturer’s in-
structions (Applied Biosystems, Inc.). The French subjects were
TaqMan genotyped using the multiplex ‘OpenArray’ platform
(Applied Biosystems, Inc.), the Australian subjects were genotyped
using the MassARRAY iPLEX system (Sequenom, Inc.), and the
Dutch genotypes were generated on the Human610-Quad Bead
GWAS array (Illumina, Inc.). Samples with missing genotypes for
more than two SNPs were excluded before analysis [applicable to a
total of 115 samples (0.5%) across all data sets]. Information on sex
and/or age at examination was available for 490% of subjects in all
case-control data sets except in the sample from Central Spain.
Samples with missing information in these categories (n = 407) were
excluded. The threshold for genotyping efficiency per SNP and data
set was set to 495%. Hardy–Weinberg equilibrium was assessed in
control subjects and in unaffected founders of the nuclear families.
Deviations from Hardy–Weinberg equilibrium were defined as
P5 0.05 based on Pearson’s 2 as implemented in PLINK v1.07
(Purcell et al., 2007).
Association analyses
All association analyses were performed using PLINK. For the case-
unrelated control data sets, logistic regression with adjustment for
age at examination and/or sex was performed where available
(Supplementary Table 1) using an additive transmission model.
Transmission equilibrium testing was applied to the UK trio data set.
Odds ratios (OR) are displayed for the allele dosage of the minor allele
as defined by the frequency in the overall data set. Meta-analyses across
all validation data sets were based on fixed-effect models. The threshold
for nominal significance was set to P5 0.01 (i.e. applying a conservative
Bonferroni correction for five tests). All P-values are one-sided with
regard to the expected direction of effect based on the original
study (IMSGC and WTCCC2, 2011). Between-study heterogeneity
was quantified using the I2 metric, and statistical significance was
assessed by the Q-test statistic. Forest plots were generated using a
customized version of the ‘rmeta’ package in R language (Lill et al.,
2012). Two-sided unweighted P-values of the original GWAS (IMSGC
and WTCCC2, 2011) and of this study were combined using METAL
(Willer et al., 2010).
Results
The combined effective replication data sets of 8499 cases, 8765
unrelated controls, and 958 trios had 80% power to detect
an odds ratio of 1.10 down to allele frequencies of 0.13.
Control genotypes in all data sets were distributed according to
Hardy–Weinberg equilibrium (P40.05) for all SNPs. Total geno-
typing efficiency was 498% for each SNP (Table 1).
Table 1 Association results for the five loci and multiple sclerosis assessed in 20 138 subjects of European descent
SNP Location (hg19) Nearest gene Validation data sets Original study Combined
P**
Eff. MAF OR (95% CI) P* I2 (95% CI) PQ OR P**
rs228614 (A/G) chr4:103,578,637 MANBA (intronic) 99.0 47.6 0.91 (0.87–0.95) 2.4  106 37 (0–71) 0.120 0.92 1.4  107 3.4  1012
rs630923 (A/C) chr11:118,754,353 CXCR5 (122 bp 5’) 98.3 15.7 0.89 (0.84–0.95) 1.2  104 1 (0–65) 0.425 0.89 2.8  107 4.7  1010
rs2744148 (G/A) chr16:1,073,552 SOX8 (36,573 bp 3’) 99.5 16.8 1.14 (1.08–1.20) 1.8  106 0 (0–14) 0.915 1.12 8.4  108 1.6  1012
rs180515 (G/A) chr17:58,024,275 RPS6KB1 (3’ UTR) 99.1 35.5 1.12 (1.07–1.17) 5.2  107 28 (0–66) 0.198 1.09 8.8  108 2.3  1013
rs6062314 (C/T) chr20:62,409,713 ZBTB46 (intronic) 99.1 7.9 0.90 (0.83–0.97) 4.3  103 31 (0–68) 0.169 0.86 1.3  107 2.3  108
Fixed effect meta-analysis results for the SNPs tested across all validation data sets were performed using PLINK. The association results from the original study (IMSGC and
WTCCC2, 2011) and this study were combined using METAL. Allele names are displayed as minor/major allele based on frequencies in the entire validation data set.
Brackets following the gene name list the location of the SNP relative to the gene, base pairs (bp) indicate upstream (5’) or downstream (3’) distance to the primary
transcript (as annotated on the UCSC Genome Browser).
CI = confidence interval; Eff. = genotyping efficiency (in %); hg19 = human genome build 19; MAF = minor allele frequency in controls (in %); OR = odds ratio;
UTR = untranslated region; * = one-sided; ** = two-sided.
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Figure 1 Meta-analysis of validation data sets assessing the association between the MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 loci
and multiple sclerosis risk in populations of European descent. The x-axis depicts the odds ratio (OR). Study-specific odds ratios (black
squares) and 95% confidence intervals (CIs, lines) were calculated using an additive model. The summary odds ratios and 95% confidence
intervals (grey diamonds) were calculated based on fixed-effect meta-analysis.
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Fixed-effect meta-analysis across all validation data sets revealed
highly significant associations of all five tested SNPs and multiple
sclerosis risk in the validation data sets, i.e. rs228614 (MANBA,
OR = 0.91, P = 2.4  106), rs630923 (CXCR5, OR = 0.89,
P = 1.2  104), rs2744148 (SOX8, OR = 1.14, P = 1.8  106),
rs180515 (RPS6KB1, OR = 1.12, P = 5.2  107), and rs6062314
(ZBTB46, OR = 0.90, P = 4.3  103). Effect estimates were similar
to those originally reported (IMSGC and WTCCC2, 2011). There was
no evidence for substantial between-study heterogeneity for any
of the five SNPs (Fig. 1 and Table 1). Combining our results with
P-values from the original GWAS (IMSGC and WTCCC2, 2011)
increased the statistical support of our findings to genome-wide
significance for each of the five tested SNPs: rs228614 (MANBA),
P = 3.4  1012, rs630923 (CXCR5), P = 4.7  1010, rs2744148
(SOX8), P = 1.6  1012, rs180515 (RPS6KB1), P = 2.3  1013,
and rs6062314 (ZBTB46), P = 2.3  108 (Table 1).
Discussion
Our study shows that common genetic variants in or near
MANBA, CXCR5, SOX8, RPS6KB1, and ZBTB46, are associated
with multiple sclerosis risk at genome-wide significance. Our
results, thus, provide compelling evidence that these loci represent
genuine genetic risk factors for multiple sclerosis.
As is the case for the majority of genetic associations, the pre-
cise molecular genetic mechanisms underlying these results still
remain to be assessed. That is, future studies need to clarify
whether the SNPs tested here are directly involved in altering
gene expression/protein function or whether such effects are
exerted by other correlated variants, possibly located in neigh-
bouring genes. For instance, SNP rs180515 in the 3’ UTR of
RPS6KB1 is located in the seed region of a predicted micro-RNA
binding site for hsa-miR-3616-5p and hsa-miR-573 and may thus
directly alter RPS6KB1 translation (Supplementary Fig. 1)
(Schilling, 2012). The intronic SNP rs228614 in MANBA is in sub-
stantial linkage disequilibrium with two non-synonymous SNPs in
the same gene [rs2866413 (p.Thr701Met), r2 = 0.87, and
rs227368 (p.Val253Leu), r2 = 0.74, based on 1000 Genomes
Pilot 1 CEU data (1000 Genomes Project Consortium, 2010)],
which may affect protein function. However, and possibly more
importantly, of all five loci tested here MANBA is the only one to
contain SNPs (including rs228614) showing strong cis effects on
messenger RNA expression based on recently published data
(Yang et al., 2010) (Supplementary Fig. 2). The intronic SNP
rs6062314 in ZBTB46 displays only moderate linkage disequilib-
rium to potentially functional variants, i.e. a non-synonymous SNP
in LIME1 [Lck interacting transmembrane adaptor 1, SNP
rs1151625 (p.Pro211Leu), r2 = 0.39], and in ZGPAT [zinc finger,
CCCH-type with G patch domain, SNP rs1291212 (p.Ser61Arg),
r2 = 0.31]. In addition, TNFRSF6B (tumour necrosis factor receptor
superfamily, member 6b, decoy) is also located in this chromo-
somal region and would represent a compelling candidate based
on its implications on T cell function (e.g. Zhang et al., 2001).
However, the only coding sequence SNP displaying noteworthy
linkage disequilibrium with rs6062314 in this gene does not
invoke an amino acid change (rs2738787, r2 = 0.36). Finally,
rs630923 maps into a potential CXCR5 transcription factor binding
site for the nuclear factor of kappa light polypeptide gene enhan-
cer in B-cells (NFKB) in a region of DNase I hypersensitivity
(ENCODE Project Consortium, 2012). Rs630923 is predicted to
alter NFKB binding (Boyle et al., 2012) and could thus, potentially
affect CXCR5 transcription.
It should be emphasized that the abovementioned potential
functional consequences are based on in silico assessments and
require experimental testing and validation. It is also possible
that hitherto unknown, rare DNA sequence variants underlie or
contribute to the observed association signals.
In summary, our study provides compelling evidence that the list
of established multiple sclerosis risk genes can now be extended
by five additional loci, all of which show genome-wide significant
association with disease risk. Further fine-mapping and functional
studies are required to elucidate the biochemical and pathophysio-
logical mechanisms underlying these associations.
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